Yükleniyor... / Loading...
This Phase 1 study examines the effect of a single dose of Prednisone, compared with placebo, on biomarkers of allergen responses in people with asthma. It included participants with mild-to-moderate asthma for at least 6 months who were clinically stable and free of respiratory infection. It was carried out in Phase 1 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Has a clinical history of mild to moderate asthma for at least 6 months, but otherwise is in good health * Participant with allergic rhinitis and asthma has a history of nonseasonal airway symptoms in response to aeroallergens OR has seasonal symptoms but can be evaluated out-of-season * Is clinically stable and free of respiratory infection or change in allergen exposure for at least 4 weeks prior to start of study Exclusion Criteria: * Has intolerance to the study drug, inhaled salbutamol, antihistamines, or any other potential asthma/anaphylaxis rescue medication * Has intolerance to lidocaine/lignocaine, sedatives, atropine or glycopyrrolate, or any other medication associated with bronchoscopy * Has taken oral parenteral corticosteroids within 8 weeks or inhaled corticosteroids/nasal corticosteroids within 5 weeks of screening and/or during the study * Has recent (4 weeks) or ongoing upper or lower respiratory tract infection * Has active allergic rhinitis at screening * Has received a vaccination within 3 weeks of screening